MA34176B1 - Composition pharmaceutique d'ibuprofène pour injection - Google Patents
Composition pharmaceutique d'ibuprofène pour injectionInfo
- Publication number
- MA34176B1 MA34176B1 MA35330A MA35330A MA34176B1 MA 34176 B1 MA34176 B1 MA 34176B1 MA 35330 A MA35330 A MA 35330A MA 35330 A MA35330 A MA 35330A MA 34176 B1 MA34176 B1 MA 34176B1
- Authority
- MA
- Morocco
- Prior art keywords
- ibuprofen
- injection
- pharmaceutical composition
- containers
- autoclave
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention sur une composition pharmaceutique d'ibuprofène pour injection qui comprend une solution aqueuse d'ibuprofène et de trométamol. Ces compositions présentent une perte minimale de principe actif et une augmentation acceptable d'impuretés après stérilisation en autoclave, des propriétés qui ont été prouvées dans divers types de récipients, tels que des récipients en matières plastiques telles que le polypropylène, le PVC et le polyéthylène, ainsi que dans des récipients en verre. Ces compositions, après avoir subi une stérilisation en autoclave, sont encore conformes aux spécifications techniques s'y rapportant de la pharmacopée européenne et de la pharmacopée US.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2010/070330 WO2011144766A1 (fr) | 2010-05-18 | 2010-05-18 | Composition pharmaceutique à base d'ibuprofène à injecter |
| PCT/EP2011/058087 WO2011144677A1 (fr) | 2010-05-18 | 2011-05-18 | Composition pharmaceutique d'ibuprofène pour injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34176B1 true MA34176B1 (fr) | 2013-04-03 |
Family
ID=43589415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35330A MA34176B1 (fr) | 2010-05-18 | 2011-05-18 | Composition pharmaceutique d'ibuprofène pour injection |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9114165B2 (fr) |
| EP (1) | EP2571488B2 (fr) |
| JP (1) | JP6018048B2 (fr) |
| KR (1) | KR101770808B1 (fr) |
| CN (1) | CN102892410B (fr) |
| AU (1) | AU2011254583B2 (fr) |
| BR (1) | BR112012029171B1 (fr) |
| CA (1) | CA2798575C (fr) |
| CL (1) | CL2012003119A1 (fr) |
| CO (1) | CO6650419A2 (fr) |
| CR (1) | CR20120559A (fr) |
| CY (1) | CY1115394T1 (fr) |
| DK (1) | DK2571488T4 (fr) |
| EC (1) | ECSP12012274A (fr) |
| ES (1) | ES2478491T5 (fr) |
| HR (1) | HRP20140622T4 (fr) |
| IL (1) | IL222497A0 (fr) |
| MA (1) | MA34176B1 (fr) |
| ME (1) | ME01834B (fr) |
| MX (1) | MX2012013402A (fr) |
| MY (1) | MY160302A (fr) |
| NZ (1) | NZ602957A (fr) |
| PE (1) | PE20130374A1 (fr) |
| PH (1) | PH12012502274A1 (fr) |
| PL (1) | PL2571488T5 (fr) |
| PT (1) | PT2571488E (fr) |
| RS (1) | RS53408B2 (fr) |
| RU (1) | RU2012154628A (fr) |
| SG (1) | SG185061A1 (fr) |
| SI (1) | SI2571488T2 (fr) |
| SM (1) | SMT201400103B (fr) |
| TN (1) | TN2012000487A1 (fr) |
| UA (1) | UA103290C2 (fr) |
| WO (2) | WO2011144766A1 (fr) |
| ZA (1) | ZA201207948B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9072710B2 (en) * | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CN104323988A (zh) * | 2014-11-27 | 2015-02-04 | 北京蓝丹医药科技有限公司 | 一种用于注射的右旋布洛芬药物组合物 |
| CN105055389B (zh) * | 2015-08-03 | 2018-08-10 | 北京蓝丹医药科技有限公司 | 一种用于早产儿先天性心脏病的布洛芬药物组合物 |
| CN105997901A (zh) * | 2016-07-27 | 2016-10-12 | 济南东方开元医药新技术有限公司 | 小儿注射用布洛芬氨丁三醇冻干粉针组合物及制备方法 |
| EP3893840B1 (fr) * | 2018-12-14 | 2025-07-09 | Fresenius Kabi Austria GmbH | Compositions pharmaceutiques pour administration parentérale comprenant de l'ibuprofène et tampon de phosphate |
| CN112526013B (zh) * | 2020-11-20 | 2022-09-06 | 人福普克药业(武汉)有限公司 | 超高液相色谱法检测布洛芬药物中有关物质浓度方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19912436A1 (de) * | 1999-03-19 | 2000-09-21 | Merckle Gmbh | Ibuprofen-Lösung |
| US20040132823A1 (en) | 2001-11-02 | 2004-07-08 | Leo Pavliv | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| DE60114249T2 (de) | 2001-11-02 | 2006-05-18 | Cumberland Pharmaceuticals Inc., Nashville | Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure |
| ITMI20040235A1 (it) | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
-
2010
- 2010-05-18 WO PCT/ES2010/070330 patent/WO2011144766A1/fr not_active Ceased
-
2011
- 2011-05-18 AU AU2011254583A patent/AU2011254583B2/en active Active
- 2011-05-18 ES ES11720479.2T patent/ES2478491T5/es active Active
- 2011-05-18 EP EP11720479.2A patent/EP2571488B2/fr active Active
- 2011-05-18 PL PL11720479T patent/PL2571488T5/pl unknown
- 2011-05-18 JP JP2013510623A patent/JP6018048B2/ja active Active
- 2011-05-18 MY MYPI2012700890A patent/MY160302A/en unknown
- 2011-05-18 DK DK11720479.2T patent/DK2571488T4/en active
- 2011-05-18 PH PH1/2012/502274A patent/PH12012502274A1/en unknown
- 2011-05-18 PT PT11720479T patent/PT2571488E/pt unknown
- 2011-05-18 KR KR1020127032850A patent/KR101770808B1/ko active Active
- 2011-05-18 ME MEP-2014-74A patent/ME01834B/me unknown
- 2011-05-18 HR HRP20140622TT patent/HRP20140622T4/hr unknown
- 2011-05-18 PE PE2012002182A patent/PE20130374A1/es not_active Application Discontinuation
- 2011-05-18 RU RU2012154628/15A patent/RU2012154628A/ru unknown
- 2011-05-18 MX MX2012013402A patent/MX2012013402A/es active IP Right Grant
- 2011-05-18 BR BR112012029171-8A patent/BR112012029171B1/pt active IP Right Grant
- 2011-05-18 UA UAA201214485A patent/UA103290C2/ru unknown
- 2011-05-18 CN CN201180024380.7A patent/CN102892410B/zh not_active Ceased
- 2011-05-18 RS RS20140366A patent/RS53408B2/sr unknown
- 2011-05-18 NZ NZ60295711A patent/NZ602957A/en unknown
- 2011-05-18 US US13/641,921 patent/US9114165B2/en active Active
- 2011-05-18 SG SG2012079570A patent/SG185061A1/en unknown
- 2011-05-18 MA MA35330A patent/MA34176B1/fr unknown
- 2011-05-18 SI SI201130206T patent/SI2571488T2/sl unknown
- 2011-05-18 CA CA2798575A patent/CA2798575C/fr active Active
- 2011-05-18 WO PCT/EP2011/058087 patent/WO2011144677A1/fr not_active Ceased
-
2012
- 2012-10-09 TN TNP2012000487A patent/TN2012000487A1/en unknown
- 2012-10-17 IL IL222497A patent/IL222497A0/en unknown
- 2012-10-17 EC ECSP12012274 patent/ECSP12012274A/es unknown
- 2012-10-22 ZA ZA2012/07948A patent/ZA201207948B/en unknown
- 2012-11-01 CR CR20120559A patent/CR20120559A/es unknown
- 2012-11-07 CL CL2012003119A patent/CL2012003119A1/es unknown
- 2012-12-17 CO CO12228358A patent/CO6650419A2/es unknown
-
2014
- 2014-07-29 SM SM201400103T patent/SMT201400103B/xx unknown
- 2014-07-30 CY CY20141100574T patent/CY1115394T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34176B1 (fr) | Composition pharmaceutique d'ibuprofène pour injection | |
| WO2007144770A3 (fr) | Bactérie | |
| EA201290498A1 (ru) | Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения | |
| NZ591146A (en) | Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills | |
| MA40571A (fr) | Composition comprenant un melange d'extraits vegetaux ou un melange de molecules contenues dans ces vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique | |
| MX2016006147A (es) | Suplemento alimenticio. | |
| CL2009000879A1 (es) | Metodo para fabricar un producto en un biorreactor que comprende cultivar microorganismos que son adaptados o mutagenizados para que exhiban por lo menos un 150% de tolerancia al producto; sistema para fabricar un producto; biorreactor. | |
| EP2392579A4 (fr) | Dérivé d'acide hyaluronique polysulfaté de faible masse moléculaire et médicament le contenant | |
| WO2008089268A3 (fr) | Méthodes et compositions destinées au traitement de troubles associés à une infection et/ou à une inflammation | |
| EP4467160A3 (fr) | Formulations liquides stabilisées et lyophilisées d'adamts13 | |
| NZ705384A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| MX350088B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| MA33220B1 (fr) | Composition pharmaceutique a proprietes anti-inflammatoires | |
| MX362168B (es) | Composiciones estables que comprenden tiabendazol y fungicidas que contienen yodo. | |
| IN2015DN02751A (fr) | ||
| BR112017014649A2 (pt) | ?isolado intestinal humano, e, composição? | |
| MX2017007675A (es) | Composiciones de polietileno con propiedades opticas mejoradas. | |
| BR112014010642A2 (pt) | polinucleotídeos, polipeptídeos e métodos para melhorar a fotoassimilação em plantas | |
| MX2010005270A (es) | Proceso de acido isoftalico simplificado para modificar pet. | |
| WO2016033572A8 (fr) | Procédé pour renforcer les numérations viables de ferments lactiques, et compositions utiles de ce procédé | |
| BRPI1008802A2 (pt) | composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição | |
| MX390196B (es) | Metodo para fabricar una composicion que comprende un anestesico local, un heparinoide y un regulador de ph. | |
| EP4282972A3 (fr) | Production d'acides gras à chaîne ramifiée et de leurs dérivés dans des cellules microbiennes recombinantes | |
| MX2012007587A (es) | Composiciones nutricionales que comprenden hojuelas de frutas que incluyen acido docosahexaenoico. | |
| PT2477503E (pt) | Processo de preparação de um produto lácteo pasteurizado e fermentado, suplementado com cálcio e vitamina d |